Prelude Therapeutics Inc insiders have been one-way buyers this past year: two people put roughly $25 million into the stock and nobody sold in open-market trades.
Bonita David P (Director) made the biggest buy, worth around $7.5 million.
Big money check: 75 institutions held PRLD as of Q2 2026, and more funds bought than sold. Looking at the quarterly pattern: No open-market insider buying or selling in the last full quarter. Insiders bought in 2 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Apr 23, 2026 | Bonita David P | Director | Buy | 1,689,189 | $4.44 | $7.5M | SEC |
| Apr 23, 2026 | Bonita David P | Director | Buy | 1,126,126 | $4.44 | $5.0M | SEC |
| Apr 23, 2026 | OrbiMed Genesis GP LLC | Director | Buy | 1,689,189 | $4.44 | $7.5M | SEC |
| Apr 23, 2026 | OrbiMed Genesis GP LLC | Director | Buy | 1,126,126 | $4.44 | $5.0M | SEC |
| Mar 27, 2025 | Combs Andrew | Executive Officer | Buy | 100,000 | $0.69 | $69K | SEC |
| Mar 27, 2025 | Vaddi Krishna | CEO | Buy | 675,000 | $0.69 | $466K | SEC |
| Mar 24, 2025 | Vaddi Krishna | CEO | Buy | 5,416 | $0.73 | $4K | SEC |
| Mar 24, 2025 | Vaddi Krishna | CEO | Buy | 15,000 | $0.73 | $11K | SEC |
| Mar 18, 2025 | Vaddi Krishna | CEO | Buy | 9,106 | $0.75 | $7K | SEC |
| Mar 18, 2025 | Vaddi Krishna | CEO | Buy | 29,999 | $0.75 | $22K | SEC |
| Mar 14, 2025 | Vaddi Krishna | CEO | Buy | 47,500 | $0.71 | $34K | SEC |
| Mar 14, 2025 | Vaddi Krishna | CEO | Buy | 50,000 | $0.72 | $36K | SEC |
| Jan 3, 2025 | Vaddi Krishna | CEO | Buy | 5,000 | $1.21 | $6K | SEC |
| Jan 2, 2025 | Vaddi Krishna | CEO | Buy | 10,000 | $1.20 | $12K | SEC |
| Dec 26, 2024 | Combs Andrew | Executive Officer | Buy | 60,000 | $1.37 | $82K | SEC |
In the last 12 months Prelude Therapeutics Inc insiders made open-market purchases worth about $25 million and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in PRLD was filed on 2026-04-23.
75 investment managers reported holding PRLD in SEC Form 13F filings for Q2 2026.
No congressional trades in PRLD were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).